Summary and next episodes
GU CONNECT has summarised the highlights from ASCO for you.
GU cancer update by Prof. Sandy Srinivas, Stanford University Medical Center, Palo Alto CA, USA.
GU CONNECT member and genitourinary oncology expert Prof. Sandy Srinivas gives us an insight into new data presented at this years ASCO 2020 virtual conference. In this video discussion with accompanying slides, Prof. Sandy Srinivas highlights drug trials of interest and gives her expert opinion on the latest results of these trials, focusing on practice changing data. The aim of these slides and video is to provide support for medical urologists and oncologists.
The HERO phase III trial and advanced prostate cancer
Focal trials include the pivotal HERO phase 3 trial which compares relugolix, an oral GnRH receptor antagonist, to leuprolide acetate, a GnRH receptor agonist, in treatment of advanced prostate cancer. Discussed is the ability of relugolix to suppress testosterone compared to leuprolide, and clinical considerations for patient suitability.
The TheraP phase II trial and metastatic prostate cancer
Prof. Srinivas then addresses the initial results from the TheraP trial, a randomised phase 2 trial comparing 177LU-PSMA-617 to intravenous cabazitaxel in metastatic castration resistant prostate cancer (mCRPC). The radiolabelled small molecule 177LU-PSMA-617 targets therapeutic β-radiation to PSMA-expressing tumours. Patient outcomes, safety, and prostate specific antigen (PSA) results from this trial are examined. From these data, in context of the phase 3 VISION trial, Prof. Srinivas comments on the potential for drug sequencing in patients with mCRPC.
The IMvigor010 phase III trial; a new concept in targeting urothelial carcinoma
Next, data is covered from the IMvigor010 phase 3 study of adjuvant atezolizumab versus observation in high-risk muscle-invasive urothelial carcinoma (MIUC). This study represents an important concept in the treatment of MIUC, for which cystectomy, with or without cisplatin-based neoadjuvant chemotherapy, is the current standard of care. This trial examines the immune checkpoint inhibitor atezolizumab as adjuvant immunotherapy following cystectomy.
The Javelin 100 trial and emerging treatments in urothelial carcinoma
Prof. Srinivas then focuses on the phase 3 Javelin 100 trial, in which the immune checkpoint inhibitor avelumab is compared to best standard of care in patients with locally advanced or metastatic urothelial carcinoma previously treated with first-line platinum chemotherapy. Underscored are results in overall survival and progression-free survival. Shortly after the ASCO 2020 conference the FDA approved avelumab as a first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma following the results from the Javelin 100 trial.
Updates in androgen deprivation therapy in non-metastatic CRPC
Lastly, Prof Srinivas discusses updates in androgen deprivation therapy (ADT) for the treatment of patients with non-metastatic CRPC. Highlighted are three trials of FDA approved drugs: apalutamide, darolutamide, and enzalutamide. Focus from new data is on improvements in overall survival and hazard ratios. We hope that you find our video overview and slides insightful.
Sandy Srinivas specializes in urologic oncology and takes care of patients with prostate, bladder, kidney, testes, penile and adrenal cancers. She has practised in this field now for more than 20 years. She is the clinical research group leader for Urologic Program at Stanford and is a principal investigator on numerous trials in urologic Oncology and is the medical director for the in-patient hematology Oncology unit.
She serves as the Vice-chair on the National Comprehensive Cancer Center (NCCN) panel for prostate cancer and has co-authored numerous publications and book chapters.
She has received numerous teaching awards and is a nationally recognized expert in the field of Urologic Oncology.
Episode
3
of 3
GU CONNECT Update from ASCO GU 2020
Episode 3: Kidney Cancer
Experts
Assoc. Prof. Martin Pichler-
Downloadable
Resouces -
5 MIN
-
Oct 2021 -
Episode
2
of 3
GU CONNECT Update from ASCO GU 2020
Episode 2: Urothelial Cancer
Experts
Assoc. Prof. Shilpa Gupta-
Downloadable
Resouces -
5 MIN
-
Oct 2021
-
Episode
1
of 3
GU CONNECT: Update from ASCO GU 2020
Episode 1: Prostate Cancer
Experts
Dr Neal D. Shore-
Downloadable
Resouces -
5 MIN
-
Oct 2021
-
Programme summary
-
Duration
5 MIN
-
Downloadable resources
Yes
-
DOWNLOAD SLIDES - PPTX
-
Language(s)
Brought to you by
GU CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.
Meet the experts
Other programmes of interest
Conference update
Oncology
Oncogene-addicted NSCLC highlights from ELCC 2026
Expert insights on the latest NSCLC data
Experts
Prof. Nicolas GirardEndorsed by
-
4 MIN
-
Mar 2026
-
Video podcast
Oncology
Pre-analytical phase challenges and biomarker testing in HER2+ metastatic breast cancer
Experts
Dr Carlos Barrios, Prof. Gary Tse, Oncology Brothers (Moderators)Endorsed by
-
Downloadable
Resources -
23 MIN
-
Mar 2026
-
Oncology
Multiple Myeloma: Is it time to rethink how we sequence treatments?
On-demand materials from an Experts Knowledge Share event
Experts
Prof. Karthik Ramasamy, Dr Joshua Richter, Dr Faisal Basheer, Dr Andrew Charlton-
Downloadable
Resources -
80 MIN
-
Mar 2026
Conference update
Episode
2
of 2
Oncology Rare diseases Endocrinology
Actualités du Congrès l’ENETS 2026
Points de vue d’experts sur les dernières données concernant le cancer neuroendocrinien
Experts
Prof. Louis de Mestier, Prof. Timon Vandamme, Dr Alice Durand-
5 MIN
-
Mar 2026
-
Conference update
Episode
1
of 2
Oncology Rare diseases Endocrinology
Update from ENETS 2026
Experts share their views on latest data in neuroendocrine cancer
Experts
Prof. Louis de Mestier, Prof. Timon Vandamme, Dr Alice Durand-
5 MIN
-
Mar 2026
-
Patient Support
Oncology Hemato-oncology Pediatrics
Personalised treatment in childhood cancer: A journey through NTRK fusion testing
Experts
Linet MenacheryEndorsed by
-
4 MIN
-
Mar 2026
-
